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ABSTRACT 
Vaccination with a poorly or not immunogenic tumor fails to protect the host from a 
subsequent challenge with the same tumor. The mechanisms underlying the failure of these 
tumors to sensitize therapeutic T cells are not clearly understood, but the inability of host T 
cells to recognize tumor has been implicated. Previous works from our laboratory have shown 
that the highly aggressive BALB/c mammary adenocarcinoma TS/A, can be rejected if 
genetically modified to express MHC class II genes upon transfection of the MHC class II 
transactivator CIITA. MHC class II molecules are required for presenting antigenic peptides 
to T helper cell and thus activate the cascade of events leading to immune effector functions 
such as antibody production and cytolytic T cell activity. 
The purpose of my thesis was to investigate whether the above approach could be generalized 
and thus extended to tumors of distinct histological origin. Moreover, it was assessed whether 
anti-tumor lymphocytes generated by this approach could be used as an immunotherapeutic 
tool for established cancers. 
Beside the previously described TS/A-CIITA breast carcinoma cells, stable CIITA-
transfectants of colon adenocarcinoma C51, renal adenocarcinoma RENCA, and sarcoma 
WEHI-164, were generated. Tumor cells transfectants were injected in vivo and their grow 
kinetics and recipient’s immune response were analyzed. Tumor rejection and/or retardation 
of growth was found for CIITA-transfected C51 and RENCA adenocarcinomas, as well as 
WEHI-164 sarcoma. As for TS/A, this tumor rejection correlated mostly with the stability and 
the amount of CIITA-induced MHC class II expression. Interestingly, mice rejecting CIITA-
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transfected tumors acquired specific immunological memory, as demonstrated by resistance to 
challenge with untransfected parental tumors. Adoptive cell transfer experiments 
demonstrated that tumor immunity correlates with CD4+ and CD8+ T lymphocytes. 
In this thesis, it is also shown that CIITA-induced MHC class II expression on tumor cells is 
able to generate antitumor therapeutic T cells. Indeed, T cells from TS/A-vaccinated mice 
were used in an adoptive cell immunotherapy (ACT) model of established tumors. The results 
showed the cure at early stages and a significantly prolonged survival at later stages of tumor 
progression. Importantly, CD4+ T cells were clearly superior to CD8+ T cells in anti-tumor 
protective function. Interestingly, the protective phenotype was associated to both a Th1 and 
Th2 polarization of the immune effectors. 
Of great importance, the T cells obtained from vaccinated mice were therapeutic also without 
other in vitro activation passages, like treatment with anti-CD3 and IL-2, differently to some 
other approaches of vaccination and ACT. Furthermore, ACT induced proliferation of tumor-
specific immune splenocytes in receiving mice, leading to rejection of subsequent tumor 
challenge or to protection from metastasis in animals h ving established tumors. 
These data support our original idea that CIITA-expr ssing tumor cells can act as antigen-
presenting cells (APCs) for their own tumor-associated antigens to CD4+ T cells, to induce 
specific and potent anti-tumor responses. These results establish the general application of our 
tumor vaccine model.  
This approach let us to envisage additional applications of this strategy for producing better 
lymphocyte effectors for adoptive anti-tumor cell immunotherapy, particularly in those cases 
of tumors non-responsive to existing therapies. 
Valeria Frangione, Ph.D. Thesis 
ABBREVIATIONS Page 5 of 77 
ABBREVIATIONS 
Ab Antibody NF-Y Nuclear Factor Y 
APC Antigen Presenting Cell pCAF p300/CBP-Associated Factor 
ACT Adoptive Cell Therapy RFX Regulatory Factor X 
CBP CREB Binding Protein s.c. Subcutaneously 
CIITA Class II Transactivator SFC Spot-forming Cell 
CREB Cyclic AMP Response Element Binding 
protein 
SRC-1 Steroid Receptor Co-activator 1 
CTL Cytotoxic T Lymphocyte TAA Tumor Associated Antigen 
DC Dendritic Cell TAP Transporter Associated with Antigen 
Processing 
ER Endoplasmic Reticulum TCR T cell Receptor 
HAT Histone Acetyl-Transferase TGF-β Transforming Growth Factor-Beta 
HLA Human Leukocyte Antigens Th1 T helper cell type 1 
IFN-γ Interferon-γ Th2 T helper cell type 2 
Ii Invariant Chain TIL Tumor Infiltrating Lymphocyte 
IL Interleukin TSA Tumor Specific Antigen 
MHC Major Hystocompatibility Complex TS/A Mammary adenocarcinoma cells 
MIIC MHC class II-containing compartment TS/A pc Mammary adenocarcinoma parental cells 
NK Natural Killer cell VEGF Vascular Endothelial Growth Factor 
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1. INTRODUCTION 
1.1.  The Immune System 
The immune system is a network of molecules, cells and organs that has evolved to recognize 
foreign substances in the body and destroy them. The targets of the immune defences are 
pathogens, such as viruses, bacteria, fungi, and other parasites. 
At the heart of the immune response is the ability to distinguish between “self”  and “non-
self”. Every cell in the body carries distinctive molecul s that distinguish it as "self". 
Normally the body's defences do not attack tissues that carry a self-marker; rather, immune 
cells coexist peacefully with other cells in a state known as "self-tolerance". Most foreign 
molecules carry distinctive markers. The immune system is able to recognize many millions 
of distinctive non-self molecules, and to respond i different ways. An "immunogenic 
antigen" is a substance capable of triggering an immune response (e.g., bacterium, virus, cells 
from another individual). 
The architecture of the immune system is multi-layered, with defences on several levels. Once 
pathogens have entered the body, they are dealt with by the "innate immune system" and by 
the "acquired or adaptive immune system". Both systems consist of a multitude of cells and 
molecules that interact in a complex manner to detect and eliminate pathogens. 
The innate system represents the first line of defence to an intruding pathogen. The response 
evolved is therefore rapid, and is unable to “memorise” the same said pathogen should the 
body be exposed to it in the future. Although the cells and molecules of the adaptive system 
possess slower temporal dynamics, they possess a high degree of specificity and evoke a more 
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potent response on secondary exposure to the pathogen indicating the acquisition of specific 
memory. 
1.2.  Major Histocompatibility Complex and Antigen Presentation 
The Major Histocompatibility Complex (MHC) is a large cluster of genes found on the short 
arm of chromosome 6 in humans (HLA; human leukocyte antigens) and on chromosome 17 in 
mice (H2) (Scheme 1). 
 
Scheme 1. Schematic overview of the genes of the MHC locus (From: Abbas and Lichtman, 2003). 
The MHC genes and their products are grouped into two classes because of their chemical 
structure and biological properties. Class I molecul s are made up of one heavy chain (45 kD) 
encoded within the MHC and a light chain, called β2-microglobulin (β2M-12 kD) encoded by 
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a different chromosome. Class II molecules consist of two (α and β) chains of similar size (34 
and 30 kD) and both encoded within the MHC. 
The products of the MHC play a fundamental role in regulating immune responses. T cells 
must recognise antigen as a complex with MHC molecules. This requires antigen to be 
processed by unfolding and proteolytic digestion before it complexes with the MHC 
molecule. Once formed the complex of antigenic peptid  and MHC are generally very stable 
(half-life ~ 24hrs). Thus, the biological role of MHC proteins is to bind small peptides and to 
"present" these at the cell surface for the inspection of T cell antigen receptors. The MHC is 
highly polymorphic and the allelic variation of MHC molecules is functionally reflected: each 
allelic product has a unique set of peptides, which it an bind with high affinity. 
The two classes of MHC molecule are specialised to present different sources of antigen. 
MHC class I molecules present endogenously synthesised antigens, e.g. viral proteins. MHC 
class II molecules present exogenously derived proteins, e.g. bacterial products or viral capsid 
proteins. The cell biology and expression patterns of each class of MHC are tailored to meet 
these distinct roles (Table 1). 
 
CELL TYPE MHC I MHC II 
T cells +++ Varies, inducible in some species 
B cells +++ ++ 
Macrophages +++ + 
Dendritic cells +++ (x10) +++ (x10) 
Granulocytes ++ - 
Endothelium ++ - (inducible) 
Hepatocytes + - 
Table 1.Expression of MHC class I and MHC class II molecules on immune cells. 
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MHC class I molecules are widely expressed, though the level varies between different cell 
types, and their function is to present fragments of pr teins that are synthesised inside the cell 
(endogenous). The peptide antigens presented in this manner are checked by killer T-cells, 
which have receptors for the class I MHC proteins. The purpose of this surveillance system is 
to identify abnormal body cells, such as those infected with viruses or those that have turned 
malignant. Such cells will display unfamiliar peptide antigens, e.g. fragments of viral 
proteins, and are attacked and destroyed. MHC class I molecules are very unstable in the 
absence of peptide. They bind peptides in the endoplasmic reticulum (ER). Peptides are 
generated continuously in the cytoplasm by the degradation of proteins, predominantly by the 
proteasome. Peptides of suitable length (~8-18 amino acids) are sp cifically transported 
across the ER membrane by a heterodimeric transporter made up of the Transporter 
Associated with Antigen Processing (TAP) molecules. These peptides bind to the class I 
MHC molecules in the ER if they have appropriate sequence motifs, the MHC molecules 
being stabilised in a partially folded state by chaperone proteins. The peptide bound class I 
MHC molecules adopt their fully folded conformation, release chaperone proteins and transit 
to the cell surface via the Golgi (Scheme 2). 
MHC class II molecules are constitutively expressed only by certain cells involved in immune 
responses, although they can be induced on a wider variety of cells. The immune cells 
expressing MHC class II molecules are specially designed to present peptide antigens derived 
from exogenous digested particles. The antigens are presented to helper T-cells (Th), which 
have receptors for MHC class II proteins. Upon recognition of MHC class II-bound peptides, 
Th cells are triggered and can subsequently activate the cascade of events leading to immune 
effector functions such as antibody production and cytolytic T cell activity. During the 
intracellular processing, MHC class II molecules bind to a third polypeptide in the ER, called 
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invariant chain or Ii. The invariant chain serves two purposes. It blocks the binding of 
peptides to the class II molecule and it targets the class II molecule to a specialised endosomal 
compartment, the MHC class II-containing compartment (MIIC). Exogenous antigens enter 
the cell in membrane vesicles, either by fluid phase pinocytosis or by receptor-mediated 
endocytosis. These vesicles fuse with the MIIC compartment. The MIIC compartment has an 
acid pH and contains proteases; this combination unfolds and degrades both the antigen and 
the invariant chain causing the generation of antige ic peptides and the release of class II 
molecules to bind those peptides with appropriate sequence motifs. Then, the class II 
molecules, peptide-complexed or "empty", traffic to the plasma membrane (Scheme 2). 
 
Scheme 2. Schematic overview of MHC class I and MHC class II (right) intracellular processing and 
antigen presentation pathways (From: Abbas and Lichtman, 2003). 
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1.3. CIITA and MHC class II molecules 
The class II transactivator (CIITA) is the master rgulator of MHC class II genes (Chang et al. 
1994; Chang et al. 1996). CIITA is a transcriptional co-activator that does not bind DNA, but 
interacts with DNA-binding proteins called RFX (regulatory factor X; consisting of 
RFX5/RFXANK-RFXB/RFXAP), CREB (cyclic AMP response lement binding protein), 
and NF-Y (nuclear factor Y; consisting of NF-YA, NF-YB, and NF-YC) (Kern et al. 1995; Zhu 
et al. 2000). All these transcription factors directly bind to the X and Y conserved cis-acting 
sequence motifs of the MHC class II promoters, and they interact with distinct or overlapping 
domains of CIITA (Scheme 3). 
CIITA also activates and regulates the transcription of genes encoding MHC class II through 
the recruitment of histone acetyl-transferases (HATs), including CREB-binding protein (CBP) 
(Kwok et al. 1994), p300, p300/CBP-associated factor (pCAF) and steroid receptor co-activator 
(SRC)-1, which can acetylate histone at lysine residues to allow gene activation (Zika and 
Ting, 2005). Thus, CIITA appears to be a focal point of interaction for both DNA-binding 
proteins specific for the MHC class II promoters and for HATs to allow chromatin opening 
(Wright and Ting, 2006) (Scheme 3). 
The MHC class II transactivator was initially identified and characterized by a somatic cell 
genetic approach. After the generation of a somatic cell mutant (Rj 2.2.5), negative for MHC-
II gene expression (Accolla et al. 1983), somatic complementation with murine MHC class II 
positive cells demonstrated the existence of a dominant locus, encoding the trans-acting 
activator. This locus was mapped to mouse chromosome 16 and designated Air-1 (Accolla et 
al. J.Exp.Med. 1985; Accolla et al, PNAS 1985; Accolla et al. 1986). Several years later, the 
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product of the human equivalent of the Air-1 locus (AIR-1) was cloned by a gene 





















































Scheme 3. The promoter of MHC class II gene. 
CIITA is absolutely required for the constitutive expression of MHC class II in B cells and 
dendritic cells and for the cytokine induction of these genes in a variety of other cell types. 
Gamma interferon (IFN-γ) is a prime example of a cytokine, which induces CIITA and 
subsequently MHC class II expression (Steimle et al. 1994). 
Two of its promoters, promoter III and promoter IV, are responsible for IFN-γ inducibility 
(Muhlethaler-Mottet et al. 1998; Piskurich et al. 1998; Piskurich et al. 1999). Promoter III contains 
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a proximal sequence that is responsible for the constitutive expression of CIITA in B cells and 
a distal sequence, which confers IFN-γ responsiveness. Promoter IV contains the major IFN-
responsive sequence (Scheme 3). 
1.4. Adaptive Immunity 
The adaptive immune system is so-called because it adapts or “learns”  to recognize specific 
antigens, and retains a “memory” of them for speeding up future responses. The learning 
occurs during a primary response to a kind of antige  not encountered before by the immune 
system. After the ending of primary response against the antigen, the immune system retains a 
"memory" of the kind of antigen that caused the reaction and this immune memory can confer 
protection up to the lifetime of the organism.  
Lymphocytes are the principal active components of the adaptive immune system. The other 
components are antigen-presenting cells (APCs), which trap antigens and bring them to the 
attention of lymphocytes so that they can mount their attack. 
Adaptive immune responses are initiated in the lymphoid tissue, in response to antigens 
presented by "professional antigen-presenting cells", which role is to activate antigen-specific 
naive T lymphocytes (Scheme 4).  
The differentiation of naive CD4+ T cells into distinct classes of CD4+ effector T cells - Th1 
or Th2, for example - depends on the effects of the cytokines present during the initial phase 
of CD4+ T-cell activation. 
Antigen-specific effector T cells and antibody-secreting B cells are generated by clonal 
expansion and differentiation over several days. 
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Scheme 4. Adaptive Immune Response. 
The effector phase of adaptive immune responses involves the clearance of extracellular 
infectious particles by antibodies (humoral immunity) and the clearance of intracellular 
residues of infection through the actions of effector CTLs, which lyse infected cells. 
In particular, Th1 response is generally involved in helping to activate the CD8+ cytotoxic T 
cells that will recognize infected cells and destroy them. Naive CD4+ T cells initially 
stimulated in the presence of IFN-γ tend to develop into Th1 cells. In part, this is because this 
cytokine induces or activates the transcription factors leading to Th1 development, and in part 
because IFN-γ inhibits the proliferation of Th2 cells. Th2 response, instead, is generally 
involved in the activation of B cells that will produce antibodies. Naive CD4+ T cells 
activated in the presence of IL-4 tend to differentiate into Th2 cells. 
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1.5 Tumor Immunology 
Tumors are a major health problem worldwide and onef the most important causes of 
morbidity and mortality. Tumors arise from the uncotr lled proliferation and spread of 
clones of transformed cells. One of the most controversial questions in immunology for over a 
century has been whether the immune system could recognize and eliminate malignant 
tumors. 
The immune system coevolved with infectious diseases in a way that allows survival of the 
host and the pathogen. In contrast, because tumors usually arise in individuals beyond 
reproductive age, they are more a problem for the indiv dual patient than for the population as 
a whole. Thus, the immune system did not develop special strategies to protect against cancer; 
instead, tumors are fought by an immune system thathas been shaped by infectious 
pathogens. Indeed, the immunobiology of cancer and infectious diseases may be overlapping, 
e.g., the recognition and elimination of both virus-infected and tumor cells seem to depend on 
similar mechanisms. 
From an immunologic perspective, tumor cells can be viewed as altered self-cells that have 
escaped normal growth-regulating mechanisms. In 1950, Macfarlane Burnet postulated the 
hypothesis of "immune surveillance" for which a physiologic function of the immune system 
is to recognize and destroy clones of transformed cells before they grow into tumours and to 
kill tumours after they are formed. Burnet proposed that the immune system defines the "s lf" 
before birth, and antigens, which make their first appearance after the immune system has 
reached maturity, would automatically be regarded as "non-self" and attacked (Burnet , 1970). 
A critical feature of the immune surveillance hypothesis is that the default reaction of the 
mature immune system to new antigens is activation, and so the major question posed to 
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cancer researchers by this hypothesis was how tumours managed to sneak through this 
surveillance mechanism. 
The tumour cells have developed a process of "immune evasion" often called "tumour escape" 
which may be a result of several mechanisms (Finke et al. 1999; Dunn et al. 2004). 
Downregulation of MHC class I expression 
Malignant transformation of cells is often associated with a reduction (or even a complete 
loss) of MHC class I molecules and the selection of MHC class I-deficient tumor escape 
variants is an important phenomenon frequently seen in human tumors (Festenstein and 
Garrido, 1986; Garrido et al. 1997; Carretero et al. 2008). 
Since CD8+ CTL recognize only antigen associated with MHC class I molecules, any 
alteration in the expression of these molecules on tumour cells may exert a profound effect on 
CTL-mediated immune response. 
Within this frame, tumor cells behave similarly to cells infected by certain viruses. Indeed, 
viruses often escape CTL recognition by using their own products to reduce MHC class I 
expression to the cell surface. This aim can be reach d in several ways, from the inhibition of 
class I transcription, the inhibition of assembly of class I heavy chain to beta-2 microglobulin, 
the inhibition of transport of the mature MHC-I heterodimer to the cell surface, etc. (Ploegh, 
1998; Yewdell and Bennink, 1999). 
Moreover, tumor-derived interleukin (IL)-10 can lead to reductions in MHC molecules (de 
Waal-Malefyt et al. 1991; Matsuda et al. 1994) and TAP expression (Salazar-Onfray et al. 1997). 
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Modulation of tumour antigens 
Certain tumour-specific antigens (TSAs) have been observed to disappear from the surface of 
tumour cells (Jager et al. 2001). Such "antigen loss variants" are common in rapidly growing 
tumours (Maeurer et al. 1996). It has also been demonstrated that clonally expanded tumour 
cells are genetically unstable and can readily acquire new mutations or downregulate tumour 
suppressor genes through epigenetic mechanisms (Hanahan and Weinberg, 2000; Vogelstein and 
Kinzler, 2004). 
Loss of signaling molecules 
In cancer patients and in some tumour-bearing mice, alterations in signal transduction 
molecules are observed in T cells and natural killer (NK) cells (Whiteside, 1999; Lai et al. 1996; 
Levey and Srivastava, 1996). 
The cytoplasmic domain of the CD3 ζ subunit in the T cell receptor (TCR) complex, for 
example, is involved in signal transduction and a decrease in its levels has been reported in T 
cells from tumor-bearing mice (Mizoguchi et al. 1992). Furthermore, alterations or decreased 
expression of these molecules were also shown in lymphocytes from colon cancer patients 
(Nakagomi et al. 1993; Matsuda et al. 1995) or in patients with renal cell carcinoma (Tartour et al. 
1995) and melanoma (Zea et al. 1995). 
These changes, although not antigen-specific, appear to start at the site of the tumour and 
eventually become detectable in peripheral blood T cells or splenocytes, suggesting that 
tumour microenvironment induces alterations in the signal transduction pathways. These 
changes in signalling molecules can often be related to "immune dysfunction" observed in the 
patients. 
Valeria Frangione, Ph.D. Thesis 
INTRODUCTION Page 23 of 77 
Products of tumour cells suppress anti-tumour immune responses 
A variety of tumor-derived factors contribute to the emergence of complex local and regional 
immunosuppressive networks, including vascular endothelial growth factor (VEGF), IL-10, 
transforming growth factor-beta (TGF-β), soluble Fas and Fas ligand. 
IL-10 and TGF-β, for example, can be produced by the tumor cells themselves or by 
infiltrating stromal cells (Kruger-Krasagakes et al. 1994). 
IL-10 has been shown to block dendritic cell-mediated priming of T cells into CTL effectors 
in vitro (Steinbrink et al. 1999), and its expression in serum appears to have negativ  prognostic 
impact in certain cancers (Wittke et al. 1999). 
TGF-β, an immunosuppressive cytokine, inhibits the proliferation and effector functions of 
lymphocytes and macrophages. TGF-β, indeed, has been shown to be sufficient to drive in 
situ expansion of regulatory T cells, thus bringing together these two evasion mechanisms 
(Peng et al. 2004). TGF-β acts also on non-transformed cells, present in the tumor mass, as 
well as distal cells in the host to suppress antitumor immune responses creating an 
environment of immune tolerance, augmenting angiogenesis, invasion and metastasis, and 
increasing tumor extracellular matrix deposition (Moutsopoulos et al. 2008). 
An additional escape mechanism adopted by tumour cells is expression of Fas ligand (FasL) 
by some tumours, which can induce apoptosis of tumor-infiltrating lymphocytes (TILs) 
(Hahne et al. 1996; Song et al. 2001). 
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1.6 Cancer Vaccination and Immunotherapy: Different Strategies 
The critical goal for immune–based approaches against cancer is from one side to create 
strategies of vaccination for preventing cancer onset and from the other side to set up 
strategies of immunotherapy, which can provide long-term and specific eradication of tumor 
cells (Berzofsky et al. 2004).  
The ability to discriminate tumor cells from normal tissues is the first step for enabling 
effective tumor destruction while minimizing toxicity (Scheme 5). 
Most non hematopoietic tumors express MHC class I molecules, but do not express MHC 
class II molecules, therefore it is generally considered that the predominant tumoricidal 
effector mechanism is killing by CD8+ T cells. Most antitumor approaches were thus focussed 








FIRST SIGNAL  
Scheme 5. Activation of specific effector CTLs by target cells, the first signal. 
1.6.1. Vaccines 
Since the discovery of tumor-associated antigens during the early 1990s, rapid progress has 
been made in identifying antigens and describing immune interactions in cancer patients (van 
der Bruggen et al. 1991; Boon et al. 1996; Boon et al. 2006). The cancer vaccine approach, in 
particular, delineates the use of active immunizations, designed to stimulate the adaptive arm 
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of the immune system directly in vivo and to induce large numbers of antigen-specific T cell 
populations with effector functions that are able to mediate immune protection against 
growing tumors. 
The idea of implement vaccines against cancer derived probably from the widespread success 
for the vaccines in the field of viral diseases prevention, that provided a considerable base of 
immunologic information on the mechanisms underlining the preventive responses and are 
easily administered to outpatients and generally do not cause significant side effects. 
In contrast to viruses and other pathogens, however, vaccines containing recombinant proteins 
or synthetic antigenic peptides usually fail to induce significant immune responses. During 
the past years, different cancer vaccines based on synthetic peptides, ‘naked’ DNA, dendritic 
cells, recombinant viruses and recombinant adenoviruses have been clinically tested. 
However, using conventional oncologic criteria for clinical tumor response (Therasse et al. 
2000), the response rate among patients was around 2-3% (Rosenberg et al. 2004). 
1.6.2. Adoptive Cell Therapy (ACT) 
The adoptive cell therapy is a passive approach for immunotherapy and represents an 
important advance in cancer immunotherapy. The powerful potential of immunotherapy to 
mediate the regression of large volumes of metastatic disease in experimental models and in 
humans was confirmed in several studies. The administration of ex vivo–activated and –
expanded autologous tumor-reactive T cells, indeed, is currently one of the few 
immunotherapies that can induce objective clinical responses in significant numbers of 
patients with metastatic solid tumors (Rosenberg et al. 2004; Rosenberg and Dudley, 2004; 
Errore. L'origine riferimento non è stata trovata.nd Rosenberg, 2003). For example, ACT after 
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lymphodepleting conditioning caused objective respon es in 46% of patients with metastatic 
melanoma refractory to other therapeutic modalities (Dudley et al. 2002), and 11% of all 
patients treated are complete responders (Ro enberg and Dudley, 2004). 
1.7 Aim of the Study 
Although, as we mentioned above, it is established that the immune system can respond 
against tumor cells, the cancer patient clinical history often demonstrates the failure of the 
immune system to eliminate the tumor (Rosenberg et al. 2004). This is mostly due to poor 
tumor-specific, MHC class-II-restricted CD4+ T cell (Th) help generated in tumor-bearing 
patients (Hung et al. 1998; Kennedy and Celis, 2008; Muranski and Restifo, 2009). Th cells, indeed, 
are required both for priming and for clonal expansio  of specific CTL following re-encounter 
with the antigen (Bennett et al. 1997; Schoenberger et al. 1998; Ochsenbein et al. 2001; Janssen et 
al. 2003; Hamilton et al. 2006) (Scheme 6).  
To optimize the antitumor immunological arms in terms of specificity and long-lasting 
memory, vaccination with tumor cells transduced with the AIR-1-encoded CIITA (Accolla et 
al. 1986; Steimle et al. 1993) has been explored in our laboratory. The hypothesis is that CIITA-
transfected cells may act as “ urrogate APC” for optimal triggering of tumor-specific Th 
cells, and thus facilitate recognition of tumor-associated antigens (TAA), presented by tumor 
cell MHC class II molecules. The induced MHC class II molecule expression, indeed, can 
elicit both the tumoricidal CTL effector mechanisms and the CD4+ help mechanisms during 
priming, to achieve full activation and effector function of tumor-specific CTLs (Bevan 2004) 
(Scheme 7). 
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Scheme 6. Activation of effector CTLs by target-specific eff ctor CD4+ T cells, the second signal. 









Effector functions: Activation of




















Scheme 7. Anti-tumoral Adaptive Immune Response. 
1.7.1. Prophylactic Approach: CIITA-Cellular Vaccine 
Previous results from our laboratory showed that complete rejection and long-lasting 
antitumor memory could be obtained after vaccination with CIITA-expressing TS/A 
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mammary adenocarcinoma cells both alive (M azza et al. 2003; Mortara et al. 2006) and in non 
replicative form (Mortara et al. 2009). Because of the potent immunogenicity of MHC class II-
positive TS/A transfectants, it became crucial to investigate whether CIITA-expressing tumor 
cells of different histological origin can be highly efficient immunogens as well. 
The results presented here demonstrate that CIITA-expressing C51 colon adenocarcinoma, 
WEHI-164 fibrosarcoma, and RENCA renal adenocarcinoma, are rejected in high percentage 
of mice and/or strongly reduced in growth. Induction of anti-tumor immunity against poorly 
immunogenic tumors depended on the ability of the MHC class II-positive tumor cells to act 
as antigen-presenting cells (APCs) during the priming phase, processing and presenting tumor 
antigens to CD4+ T cells, and hence to trigger CD4+ T cells, which in turn induce stimulation 
and maturation of CTL effectors.  
Importantly, the results show that immune CD4+ helper T cells can induce protective 
antitumor responses in naïve mice injected with parent l untransfected tumor cells. Since 
tumor rejection required also CTL, these results imply that primed CD4+ T cells, with 
functional characteristics of T helper 1 (Th1) cells producing IFN-γ, can play a more direct 
role in the effector phase of tumor rejection by inducing the priming and maturation of naïve 
anti-tumor CTL effectors.  
1.7.2. Therapeutic Approach: Adoptive Cell Immunotherapy 
The other important goal in tumor immunology is immunotherapy of established tumors. 
Adoptive cell therapy (ACT) has been considered as a possible approach. Although at clinical 
level ACT results are still preliminary (Rosenberg et al. 2008), nevertheless the importance of 
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including CD4+ T helper cells together with CD8+ T cells to induce optimal therapeutic 
effects has been established (Antony et al. 2005; Dudley et al. 2005). 
The generation of strong and reproducible anti-tumor effectors after vaccination with CIITA-
tumor cells encouraged us to investigate their use in ACT immunotherapeutic approaches and 
to develop an efficient method to induce tumor-specific CTL in vivo. 
In an effort to determine the components of successful immunotherapy in a relevant model of 
established cancer, it was decided to study the feasibility of adoptive immunotherapy 
approach to treat established tumor at early stages that mimic clinical situations like 
metastases or recidives following surgical or radiotherapy. 
Antitumor efficiency of CIITA-based vaccine and adoptive therapy are dependent in part on 
the ability of tumor-specific T cells to persist long-term and retain antitumor function in vivo. 
Ideally, with respect to effective tumor therapy and vaccine development, such approaches 
would not only induce tumor regression and prevent tumor relapse, but also initiate and 
amplify effective endogenous recipient T cell-tumor cell interactions. 
The genetic modification of tumor cells with CIITA gene could allow generation of an 
unlimited supply of autologous antitumor CD4+ T cells that in turn could prime in vivo 
antitumor effector CD8+ T cells. Our results indicate that these effectors can potently 
counteract tumor growth. These data will be discussed within the frame of the present 
knowledge of host’s adaptive immune response against the tumor and in the perspective of 
establishing better strategies for preventing and/or treating cancer. 
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2. MATERIALS AND METHODS 
2.1. Animal Tumor Models 
BALB/c tumor cell lines, TS/Apc, mammary adenocarcinoma (kindly provided by P.L. 
Lollini, University of Bologna, Italy; Nanni et al. 1983), RENCA, renal adenocarcinoma, C51, 
colon adenocarcinoma (kindly provided by M. P. Colomb , Istituto Nazionale per lo Studio e 
la Cura dei Tumori, Milan, Italy), and WEHI-164 fibrosarcoma were cultured in DMEM 
supplemented with L-glutamine, HEPES, and 10% heat-inactivated fetal calf serum in a 5% 
CO2 atmosphere at 37°C. 
5- to 10- week-old female BALB/c (H-2Kd) mice were purchased from Harlan (Oxon, UK). 
Housing, treatment and sacrifice of animals followed national legislative provisions. 
2.2. Plasmids and DNA transfection 
The full-length human CIITA cDNA was obtained by pre arative proofreading PCR (Fusion 
Taq; Finnzymes, Helsinki, Finland) from pREP10-CIITA plasmid, previously described 
(Sartoris et al. 1996). Forward and reverse primers bear Xho-I linker tails used to subclone the 
PCR product into the pLXIN2.ape retroviral vector (from Antonio Daga, Department of 
Translational Oncology, IST-National Cancer Research Institute, Genoa, Italy), modified 
from pLXIN retroviral vector (Clontech, Milan, Italy) to include additional restriction sites in 
the MCS. 
DNA transfections were performed with Lipofectamine™ 2000 (Invitrogen SRL, San 
Giuliano Milanese, Italy), according to the manufacturer’s instructions. TS/A, WEHI-164, 
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C51 and RENCA tumor cells were transfected with 3µg of pLXIN (mock) or pLXIN-CIITA 
plasmid. Stable transfectants were selected in culture medium containing G418 (500µg/mL) 
and cloned by limiting dilution. 
2.3. Flow cytometry analysis 
Transfected cell lines were surface-stained with 20.8.4S anti-H2-Kd and K22–422 anti-I-Ed 
mAbs. A FITC-conjugated goat anti-mouse immunoglobuin (BD Becton Dickinson Italia 
S.p.A., Buccinasco, Milan, Italy) was used as a second step reagent. The phenotype of all cell 
types was analyzed by an EPICS® XL flow cytometer and EXPO32® analysis software 
(Beckman Coulter S.p.A., Milan, Italy). 
2.4. Vaccination 
Animals were injected subcutaneously with 3.5x106 (WEHI-164) or 2x105 (RENCA) or 
1.5x105 (C51) or 5x104 (TS/A) parental cells or with the same dose of correspondent mock 
transfected cells (empty plasmid) or CIITA-expressing cells in 100µl RPMI 1640. 
Tumor growth was inspected every 2-3 days, size measur d by a caliper and recorded as the 
tumor area (mm2). 
Rejecting animals were rechallenged with the same tumorigenic dose of parental cells 
subcutaneously (s.c.) on the same flank. Experiments were performed two times with groups 
of four to six mice. 
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2.5. Adoptive Transfer (Winn Assays) for Vaccine-induced Immunity  
The ability of various lymphoid spleen cell populations from CIITA-tumor vaccinated and 
rechallenged mice with parental tumor cells to transfer antitumor resistance to syngeneic 
recipients was assessed four weeks after tumor rechall nge (day 28). The spleen cells were 
aseptically collected from the mice, in which neithr the CIITA-expressing neither the 
parental tumor grew, pooled for each treatment group and used for the Winn assay. CD4+ or 
CD8+ cells were purified from the total spleen cell suspension (depleted of red blood cells), 
by negative immunomagnetic sorting using the CD4+ or the CD8a+ T Cell Isolation Kit 
(Miltenyi Biotech GmbH, Bergisch Gladbach, Germany).  
The separation was performed according to the manufacturer’s instruction without 
modification. Briefly, negative selection was performed with a pool of mAb specific for all 
cells except CD4- or CD8-positive cells. Purity was >95%, as assessed by 
immunofluorescence. The total or purified splenocytes from protected mice or age-matched 
parental tumor-bearing mice were admixed with viable tumor cells in a volume of 0.1 ml PBS 
(E:T=80:1 for C51 tumor model or E:T=1:1 for WEHI-164 tumor model). The mixture was 
inoculated s.c. at the inguinal region of BALB/c recipient mice. 
2.6. Ex-vivo derived tumor cells 
Suspensions of single cells, derived from outgrowing tumors in mice injected with CIITA-
expressing tumor cells, were growth in vitro and analyzed for MHC class II expression. 
Briefly, biopsies of tumors were removed under sterile conditions, dissociated with a sterile 
syringe plunger in a cell strainer with 70µm nylon mesh (BD Becton Dickinson Italia S.p.A., 
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Buccinasco, Milan, Italy), resuspended and growth in complete DMEM medium, until the 
time of flow cytometric analysis. 
2.7. Adoptive Cell Therapy (ACT) 
5–12 weeks old female BALB/c mice of age (six groups, n = 4–5 for group) were injected 
subcutaneously on the left flank with 5x104 TS/A mammary adenocarcinoma cells (TS/A-pc) 
in 100µl of RPMI 1640. Each group was then injected, at dis inct days after tumor inoculum, 
near the tumor inoculation sites, with 5x106 immune splenocytes derived from mice 
vaccinated with TS/A-CIITA and rejecting TS/A parental cells. 
Briefly, donor BALB/c mice were immunized against the parental tumor by injecting them 
s.c. on the left flank with 1x105 CIITA-expressing TS/A cells. Boost with the same 
tumorigenic dose of parental TS/A (TS/A-pc) in TS/A-CIITA-rejecting animals was carried 
out s.c. on the same flank. The immunized mice were used as onors 2 weeks after the 
parental tumor boost. Spleens were removed under sterile conditions, dissociated with a 
sterile syringe plunger in a cell strainer with 40µm nylon mesh (BD Becton Dickinson Italia 
S.p.A., Buccinasco, Milan, Italy), treated with ACK buffer (150mM NH4Cl; 10mM KHCO3; 
0.1mM EDTA; pH 7.4) and single cell suspensions resuspended in RPMI 1640. Then, tumor-
bearing mice were injected with 5x106 effector spleen cells suspended in 100µl of RPMI 
1640. 
Tumors were measured twice weekly, and sizes recordd as the tumor area (mm2). All 
experiments were performed in a blinded, randomized fashion and repeated independently at 
least twice, with similar results. Control group for these studies included mice receiving no 
splenocytes. The same tumor-immune splenocytes used for adoptive immunotherapy were 
Valeria Frangione, Ph.D. Thesis 
MATERIALS and METHODS Page 34 of 77 
admixed at 4°C in proportions of 100:1 (E:T) with TS/A-pc tumour cells and immediately 
thereafter, 0.2 ml of the suspension was inoculated s.c. on the left flank of naive animals. 
2.8. Adoptive Transfer (Winn Assays) for Therapy-induced Immunity  
Winn assay experiments were performed also to demonstrate antitumor protective cells in the 
spleen of adoptive therapy-treated tumor-bearing mice, sacrificed 30 days after tumor cells 
inoculum. 
Naïve mice were injected s.c. with a mixtures of 5x104 TS/A tumor cells and 1x107 freshly 
isolated total splenocytes (E:T ratio of 200:1) from n-day-6-treated tumor-bearing mice or 
from control untreated tumor-bearing mice. Furthermore, to study the T cell subpopulations 
involved in antitumor effect, polarized CD8+ and CD4+ T cells were isolated from on-day-6-
treated tumor-bearing mice splenocytes.  
Enriched CD8+ (2x106 cells) and CD4+ T cells (3x106 cells) were admixed with TS/A (5x104) 
tumour cells in a proportion equivalent to CD8+ and CD4+ subtypes percentages in total 
spleen and inoculated s.c. on the left flank of naïve animals. 
2.9. ELISPOT assay 
Mouse IFN-γ and IL-4 ELISPOT assays were used to detect the presence of spleen cells 
responsive to tumor cells in BALB/c mice immunized with the CIITA-transfected cells or 
cured with adoptive immunotherapy. MultiScreenTMHST 96-well Immobilon-P Membrane 
plates (Millipore S.p.A., Vimodrone, Milan, Italy) were coated with 100 µl of capture MM-
701 Anti-Mouse Interferon-γ or MM-450D Anti-Mouse Interleukin-4 (TEMA ricerca S.r.l., 
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Bologna, Italy) Purified Monoclonal Antibodies in PBS (10µg/ml) and left 2 h at 37°C. The 
plates were blocked with PBS-BSA 2% for 2 h at 37°C and then washed with PBS. 
Responder T cells derived from the spleens of mice were added to each well (3x105 cells) in 
100µl complete RPMI medium containing 10% fetal calf serum, 2mM L-glutamine, 100U/ml 
penicillin/streptomycin. Control wells contained responder splenocytes plus medium alone or 
plus Concavalin A (ConA, 10µg/ml). 
Stimulator Mitomycin C-treated (60µg/ml for 2 h at 37°C) target tumor cells (105 cells) or 
gp70-derived AH1 peptide (SPSYVYHQF, synthesized by Primm S.r.l., Milan, Italy) 
(10µg/ml) were added to each test well at a responder:stimulator ratio of 3:1. 
In certain experiments, mAb specific for either MHC class I (20.8.4S clone, 50µg/mL) or 
class II (K22.42.2 clone, 50µg/mL) antigens were added during the co-culture with irradiated 
tumor cells. 
After 48h, the plates were washed with PBS-Tween20 (0. 5%). Detection MM-700-B Anti-
Mouse Interferon-γ or MM-450D-B Anti-Mouse Interleukin-4 Monoclonal Biotin-Labeled 
(2µg/ml) Antibodies (TEMA ricerca S.r.l., Bologna, Italy) were then added to each well, and 
the plates were left for 3 h at room temperature in the dark.  
After further washing, N100 HRP-Conjugated Streptavidin (1:5,000) (TEMA ricerca S.r.l., 
Bologna, Italy) was added for 2h at room temperature. Colour was developed with AEC 
Chromogen Kit (Sigma-Aldrich Italia Srl, Milan, Italy). 
The reaction was stopped after 4-6 min, with deionized water. The resulting spots were 
counted using a stereomicroscope. 
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The frequencies were then expressed as cytokine producing cells per million splenocytes. A 
>2-fold increase in the number of spots over the control (splenocytes cultured in the absence 
of tumor cells) was considered a positive response. 
Data are expressed as number of spot-forming cells p r million spleen cells. 
2.10. CTL Activity Assay 
CytoTox 96 cytotoxicity assay (Promega Italia s.r.l., Milan, Italy) was used to measure the 
splenocyte cytotoxic activity in treated mice according to the manufacturer’s protocol with 
minor modification. Briefly, splenocytes were freshly isolated and incubated in the presence 
of Mitomycin C-treated (60µg/ml for 2 h at 37°C) tumor parental and CIITA-expressing 
target cells, at 50:1 effector-to-target cell ratio. 
After 5 days, splenocytes were used as effector cells in the CTL assay. Parental tumor cells 
were used as target cells and were plated at 1x104 cells per well on 96-well U-bottomed 
plates, and splenocytes (effectors) were added to afinal volume of 100µL, in different 
effector-to-target cell ratios (50:1, 25:1, 12:1, and 6:1). Plates were then incubated for 4 h in a 
humidified 5% CO2 chamber at 37°C and centrifuged at 500xg for 5 min. Aliquots (50µL) 
were transferred from all wells to fresh 96-well flat-bottomed plates, and an equal volume of 
reconstituted substrate mix was added to each well.The plates were then incubated in the dark 
at room temperature for 30 min. Stop solution (50µL) was then added, and absorbance values 
were measured at 490 nm. Cell death percentages at ach effector-to-target cell ratio were 
calculated using [A (experimental) – A (effector spontaneous) - A (target spontaneous)] x 100 
/ [A (target maximum) - A (target spontaneous)]. 
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2.11. Immunohistochemical analysis 
Three mice each from TS/A tumor or on-day-6-adoptive herapy-treated TS/A tumor groups 
were euthanized at 14 days after s.c. tumor inoculation. Cryostat sections (6µm thick) were 
immunostained using a streptavidin-biotin-alkaline phosphatase complex staining kit (Bio-
Spa Division, Milan, Italy) and naphthol-AS-MX-phosphate and Fast Red TR (Sigma, St. 
Louis, MO) to visualize binding sites. The mAbs used were anti-CD4 (GK1.5), anti-CD8 
(2.43), anti–dendritic cells (DEC-205; clone NLDC-145; ImmunoKontact, Lugano, 
Switzerland), anti-polymorphonucleate Ly-6G (Gr-1; clone RB6-8C5) and anti-macrophage 
(clone MOMA-1; ImmunoKontact). The sections were incubated with the primary antibody 
overnight at 4°C. The red reaction product was obtained using a mixture of 2mg naphthol-AS-
MX-phosphate dissolved in 200µL N,N-dimethylformamide (Sigma) and diluted in 9.8mL of 
0.1mol/L Tris-HCl (pH 8.2) and 1 mmol/L levamisole (Sigma). Immediately before use, 
10mg Fast Red TR salt was added. Gill’s haematoxylin was used as a counter stain and the 
sections were mounted in glycerol (DAKO, Carpinteria, CA). Cell counts were obtained in 8 
to 12 randomly chosen fields under a Leica Wetzlar light microscope (Solms, Germany) at 
x400 magnification, 0.180mm2/field. Mann-Whitney U test was used to evaluate whether 
there was a statistically significant difference between TS/A and adoptive therapy-TS/A 
cellular infiltrate. Data analyses were considered highly significant when P < 0.005. 
2.12. Statistical Analysis 
Mean values ±SEM were calculated for each group at each time. Average tumor sizes were 
plotted over time to display the trend of tumor development in each treatment group. All 
statistical analyses were done using the Student’s t test to evaluate significance between 
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groups, except that the log-rank statistics was used to test differences between groups. For all 
cases, results were regarded significant if P values w re <0.01 or <0.05. All in vivo 
experiments were performed two times with groups of four to six mice, and the results were 
cumulated as they gave homogeneous results. 
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3. RESULTS 
3.1. Rejection of CIITA-tumors and protective immunity against 
parental tumors. 
To evaluate the ability of naïve mice to reject CIITA-expressing tumors, tumor cell lines of 
different histotype that causes 100% mortality in BAL /c mice were used. As shown in 
Figure 1A, in these tumor cell lines, the absence of MHC class II gene transcription correlates 
with the lack of CIITA expression. The transfection f CIITA gene, indeed, induces de novo 
expression of MHC class II molecules into the tumor cell lines. Morphology and growth 
kinetics in vitro of transfected cells did not differ with respect to untransfected parental cells 
(data not shown). 
When CIITA-transfected tumor cells were injected in vivo, complete rejection or significant 
delay in tumor growth was observed in all tumor models, when compared to parental tumors 
and to tumor cells transfected with the mock vector (Figure 2A-B, *P<0.01). CIITA 
expression indeed can inhibit tumor growth in 100% of animals implanted with WEHI-CIITA 
cells and 80% of animals implanted with C51-CIITA cells, contrary to parental WEHI and 
C51 cells for which tumor take was 100%. Importantly, in the remaining 20% of C51-CIITA 
injected mice, tumors developed much later as compared to C51 parental tumors. Although 
not completely rejected, the RENCA-CIITA tumor grew more slowly than did tumors 
induced by the parental cells, suggesting that the immune response generated was ineffective 
for a complete tumor rejection (Figure 2A-B). 
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Capacity to reject the tumor correlated with the amount and stability of CIITA and thus 
corresponding MHC class II expression (Meazza et al. 2003). Indeed, ex vivo-isolated cells 
from C51-CIITA tumor-bearing mice showed decreased MHC class II expression; more 
importantly ex vivo-isolated cells from RENCA-CIITA tumor-bearing mice, which displayed 
only retarded tumor growth, showed an almost complete loss of MHC class II expression 
(Figure 1B). The reasons of the reduced stability of CIITA expression in vivo in RENCA 
cells are under investigation. 
It was next evaluated whether initial vaccination with the CIITA-expressing tumor cells 
would induce a memory response against the parental cells. Thirty days after vaccination, 
tumor-free mice were challenged with parental cells. 100% of animals vaccinated with 
WEHI-CIITA and with C51-CIITA showed complete rejection. This protective response was 
long lasting, since 90 days post-vaccination animals were still able to reject a second tumor 
challenge (Table 2). Thus, vaccination with CIITA-mediated MHC class II expressing tumors 
results in long lasting, specific anti-tumor immunity against MHC class II negative parental 
tumor cells. 
3.2. Role of CD8+ effector and CD4+ T helper cells in CIITA-Vaccine 
approach. 
To verify whether the effector function in challeng experiments of tumor rejection was 
mediated by specific lymphocyte subpopulations, CD4+ and CD8+ spleen cells of mice 
rejecting the CIITA-tumor vaccine and a parental tumor challenge were used to protect naïve 
animals in adoptive transfer experiments. These experiments were performed using total 
spleen cells or the equivalent proportion of purified CD4+ or CD8+ tumor-immune 
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splenocytes. Mice were inoculated with effector (E)and tumor (T) cells, with an 80:1 (E:T) 
proportion for C51 cells and a 1:1 (E:T) proportion f r WEHI-164 cells. 
As shown in Figure 3, unselected spleen cells for both WEHI-CIITA and C51-CIITA 
vaccinated and challenged mice protected 100% of injected mice from tumor growth. 
Interestingly, purified CD4+ T cells were extremely potent in protecting mice from WEHI 
tumor take, as 80% of the animals were protected and the remaining 20% manifested a 
retarded growth (Figure 3A, upper panels). Purified CD4+ T cells were also efficacious in 
preventing tumor growth of C51 tumor, as 50% of theanimals were protected and the 
remaining 50% displayed a significant tumor growth retardation (Figure 3A, lower panels). 
Similar results were obtained when immune CD8+ T cells were used in adoptive transfer; in 
this case 60% of WEHI injected mice (Figure 3A, upper panels) and 100% of C51 injected 
mice were protected (Figure 3A, lower panels). 
These results strongly indicate that both CD4+ and CD8+ T cells can act as effectors against 
the tumors if previously triggered by MHC class II-positive tumor cells. It was subsequently 
assessed whether mice resistant to tumor take could reject a tumor challenge after 1 month 
from adoptive cell transfer. Animals rejecting WEHI tumors after total spleen cell, CD4+ or 
CD8+ T cell transfer were able to reject in 100% of the cases a tumor rechallenge (Figure 3B, 
left panel). Similarly, mice rejecting C51 tumors after total spleen cells or CD4+ T cell 
transfer acquired immunological memory and rejected in 100% of the cases a tumor 
rechallenge, whereas only 50% of mice rejecting the tumor after CD8+ cell transfer were 
resistant to a further rechallenge (Figure 3B, right panel)  
These results demonstrate that CIITA-induced tumor-i mune T cells protect naïve mice and 
that the antitumor responses induced with CIITA-based vaccination is dependent mostly on 
CD4+ and CD8+ T cells, able to induce also alone transplantable memory responses. Of great 
Valeria Frangione, Ph.D. Thesis 
RESULTS Page 42 of 77 
importance, it was shown also that not only CIITA-vaccine-induced CD8+ CTLs, but also 
CD4+ helper T cells can induce effector antitumor respon es. Finally, it was also shown that 
this anti-tumor memory is long lasting, as 90 days fter the first challenge tumor-free animals 
in the all three groups are still able to reject a second challenge with parental cells (data not 
shown). 
3.3. CIITA-tumor-mediated CD4+ T cell priming and generation of 
anti-tumor CTLs 
CD8+ CTL are major effectors in killing the tumor cells in vivo. However, as show above in 
our experimental system primed CD4+ T cells transferred into naïve recipients can protect he 
animals likewise. To assess the importance of CD4+ T cells in the generation of anti-tumor 
CD8+ cytolytic activity, we investigated the CTL responses in both WEHI-CIITA and C51-
CIITA vaccinated mice, 4 weeks after vaccination, ad in naïve mice receiving adoptive cell 
transfer of anti-tumor immune lymphocyte subpopulations. 
Mice were vaccinated with CIITA-expressing WEHI or C51 tumor cells, as described above. 
At week 4, splenocytes from the mice in each group were harvested and pooled. CTL 
responses specific to tumor cells were measured following antigen restimulation in vitro. 
Vaccinated mice developed a strong CTL activity (Figure 4A,C). A second interesting step 
was determining if vaccination can induce CTL responses able to be transplanted in naïve 
mice. As shown in Figure 4B and Figure 4D, after adoptive transfer, CTL activity was higher 
in animals that received CD4+ T cells as compared to animals receiving CD8+ T cells. Indeed, 
CTL activity generated by CD4+ T cell transfer was as high as the one generated by total 
spleen cell transfer for both WEHI and C51 tumors. CTL activity was strongly reduced in 
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presence of anti-MHC class I, but not anti MHC class II, antibodies (data not shown). These 
results strongly suggest that anti-tumor primed CD4+ T cells generated by the vaccination 
procedure with CIITA-transfected tumors support theactivation of naïve CD8+ T cells to 
become fully differentiated anti-tumor CTLs. 
3.4. ACT by CIITA-cell vaccine induced immune effectors 
We subsequently investigated whether anti-tumor immune lymphocytes could be used for 
adoptive cell therapy (ACT) of established tumors. For this approach we used effectors 
generated in the more extensively studied TS/A-CIITA vaccination system (Meazza et al. 2003; 
Mortara et al. 2006; Mortara et al. 2009). Vaccination experiments were repeated with TS/A-
LXIN-CIITA tumor cells (data not shown) and confirmed the efficacy of TS/A-LXIN-CIITA 
clone to induced effective protection i  vivo, fully comparable to our previous results with 
TS/A-CIITA 32.10.7 clone (Mortara et al. 2006). Donor TS/A-LXIN-CIITA-rejecting mice 
were boosted one time with TS/A-pc tumor cells, 2-weeks before the adoptive transfer in 
tumor-bearing mice. 
Treatment with tumor-immune splenocytes, up to day 6 fter tumor inoculum, was efficient in 
curing or significantly retarding tumor growth. As showed in Figure 5A,B, all untreated mice 
developed tumors, but, at day 0, day 1 and day 3 after tumor inoculum, immune spleen cells 
(ACT day 0, 1, and day 3) completely and stably cured 100%, 75% and 50% of the tumors, 
respectively, and strongly retarded tumor growth in the remaining 25% (day 1) and 50% (day 
3) of tumors. Injection of immune cells at day 6 (ACT day 6), time in which mice displayed 
already an evident tumor mass, although not curing, was instrumental in retarding tumor 
growth as observed in the non cured mice after ACT at day 1 and 3. Injection of immune 
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spleen cells 12 days after tumor inoculum (ACT day 12) was instead inefficient either in 
protecting or retarding the growth of the subcutaneously inoculated mammary 
adenocarcinoma. Animals injected with splenocytes did not show signs of discomfort and 
their mean body weight did not differ from that of the controls (data not shown). 
Cures were defined as those animals that were tumor-free after treatment for at least 30 days. 
It was then investigated whether tumor rejection geerated by ACT (i.e., day 0, day 1 and day 
3) was long-lasting. Cured animals were rechallenged with TS/Apc 30 days after ACT to 
determine the presence of immunologic memory. 
All ACT-protected mice rejected the subsequent parent l tumor challenge (Table 3), 
indicating again the capacity of transferred immune cells to persist in vivo and retain 
immunological memory. 
3.5. Therapeutic effect of T-cell subsets. 
The fact that a strong retardation of tumor growth as achieved by ACT after 6 days from 
tumor inoculum prompted us to assess whether immune effectors from these animals were 
able to influence the tumor take and/or growth when coinjected with tumor cells into naïve 
animals. 
Total spleen cells (Tot sc), were fully competent in protecting naïve mice from tumor take in 
100% of the animals (Figure 5C,D). Interestingly, CD4+ T cells fully protected 60% of the 
animals and strongly retarded tumor growth in the remaining 40% of mice. 
On the other hand, CD8+ T cells were incapable of fully protecting the animals, although they 
were still able to strongly delay tumor growth. As negative control, the adoptive transfer of 
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total splenocytes from not treated TS/A tumor-bearing mice (C sc) did not affect tumor 
growth. Thus, immune lymphocytes, and particularly CD4+ T cells had a stronger anti-tumor 
protecting activity than CD8+ lymphocyte effectors. 
3.6. CTL responses in ACT-treated mice. 
TS/A tumor-bearing mice were treated with CIITA vaccine-induced tumor immune spleen 
cells as described above. After 4 weeks, splenocytes from mice of each group (0, 1, 3, 6, 12 
days) were taken and CTL responses specific to tumor cells were measured, following antigen 
re-stimulation in vitro. 
Representative results, referred to spleen cells of ACT at day 3 and day 6, are shown in 
Figure 6A. The group of cured mice (ACT day 3) developed a higher level of parental tumor-
specific lytic activity than those injected with parental tumor cells alone (Untreated tumors). 
Those mice that were not cured, but had significantly reduced tumor growth kinetics, 
displayed a reduced but still significant cytolytic a tivity (ACT at day 6). 
We then assessed the CTL response of spleen cells of mice that were protected when 
coinjected with tumor cells and total spleen cells from ACT day 6-treated animals (refer to 
Figure 5C and Figure 5D). 
Interestingly, a very strong CTL activity was observed in these mice (Figure 6B), perhaps 
because these CTL responses were less anergized by tumor microenvironment and gave very 
high cytotoxic signals compared to ACT at day 6 in Figure 6A. 
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Taken together, these results show that the anti-tumor effector response, generated in mice 
undergoing adoptive cell immunotherapy, was only quantitatively, but not qualitatively, 
insufficient in controlling and counteracting tumor growth. 
3.7. Adoptive cell therapy induces a massive infiltrat on of TS/A 
tumors by CD4+ T cells, CD8+ T cells, dendritic cells and 
granulocytes.  
In order to assess the modifications induced by ACT in the tumor microenvironment we then 
studied by immunohistochemistry the tumor tissue and particularly the phenotype and number 
of infiltrating leukocyte subpopulations in mice undergoing ACT at day 6, and specifically 8 
days after ACT (14 days after tumor inoculum). At this time point massive infiltration of 
CD4+ T cells, CD8+ T cells and dendritic cells was observed in TS/A tumor masses as 
compared with the virtually absent representation of these lymphocyte subpopulations in the 
tumor of mice not undergoing ACT (Figure 7A). On the other hand, macrophages, which 
were observed at discrete number already in the untreated parental TS/A tumor 
microenvironment, were not statistically increased after ACT. Importantly, instead, a very 
significant increase of granulocytes (PMN) was present in the tumor tissue after ACT. 
Although this experiment did not allow to establish exactly the origin of the leukocyte 
infiltrate, i.e. whether exclusively deriving from ACT cells or also from host cells, it is certain 
that PMN infiltration is of exclusive host derivation, as only splenic lymphocytes and 
monocytes from immune mice were used in the ACT regim n. However it appears plausible 
that most of the lymphocyte subpopulations, particularly the CD8+ CTL effectors were from 
the ACT derivation, since already at this very early time point the tumor microenvironment 
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displayed extensive areas of necrosis, as shown in Figure 7B (necrotic area -nec- is depicted). 
A very similar aspect of the tumor tissue was observed in mice undergoing ACT at day 0, 1 
and 3, with even more dramatic increase in the number of necrotic areas observed (data not 
shown), compatible with the superior rejecting capacity of ACT at these time points. 
3.8. Tumor-specific mixed Th1-Th2 immune responses aft r ACT. 
To get further information on the characteristics of immune responses taking place in ACT-
treated mice, we investigated tumor-specific IFN-γ- and IL-4-producing spleen cells, at 4 
weeks from tumor inoculum, in tumor-rejecting mice after day 3 ACT, or of mice with 
delayed tumor growth after day 6 ACT (Figure 8). 
Increased frequency of tumor-specific, IFN-γ-producing spleen cells was observed in tumor-
cured mice (Figure 8A, left panel, ACT tum−) but not in day-6 ACT treated mice (Figure 8A, 
left panel, ACT tum+) when splenocytes were re-stimulated in vitro with TS/A-CIITA cells, 
TS/Apc or the AH1 peptide. 
The number of spleen cells producing IFN-γ in response to in vitro stimulation with AH1 
peptide, an immune-dominant peptide of the gp70 envglycoprotein of an endogenous 
retrovirus recognized by MHC-I-restricted CTLs on TS/A tumors (Huang et al. 1996), was 
higher in tumor-free than in tumor-bearing mice (Figure 8A). 
Interestingly, the IFN-γ-specific response of tumor-cured mice was strongly inhibited by anti-
MHC-II antibodies and, to much lesser extent by anti-MHC-I antibodies, suggesting a Th1-
type response attributable mostly to CD4+ T cells (Figure 8A, right panel, ACT tum−). 
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The frequency of IL-4-producing cells was also increased in tumor-cured mice particularly 
when spleen cells were restimulated in vitro with TS/A-CIITA and parental TS/A tumor, but 
not with the AH1 peptide (Figure 8B, left panel, ACT tum−). 
Moreover and at variance with results found for IFN-γ producing cells, significantly higher 
numbers of IL-4 producing cells were also observed in ACT tumor-bearing mice (Figure 8B, 
left panel, ACT tum+) when restimulated in vitro with all three stimuli used. Also in this case 
the major IL-4-producing spleen cells in both tumor-cu ed and slow-growing tumor-bearing 
mice was predominantly attributable to CD4+ T cells, as it was strongly inhibited by anti-
MHC-II, and not anti-MHC-I, antibodies (Figure 8B, right panel, ACT tum+). 
These results indicate that a mixed Th1-Th2 type of response, mainly attributable to CD4+ T 
cells, was present in animals cured by ACT.  
On the other hand, animals, which could not be cured by ACT, although displaying slow-
growing tumors, had a predominant CD4+ Th2-type of response. These antitumor immune 
responses in vivo are very persistent, since we can detect it in the spl en cells of cured mice 
also after 1 month from tumor injection. 
3.9. Tumor-specific mixed Th1-Th2 immune responses after Winn 
Assays 
It was therefore important to assess whether the polarization of the immune response in day 6 
ACT-treated mice was conserved when spleen cells of these mice were used in adoptive cell 
transfer admixed with tumor cells, as we knew these cells were capable to fully protect from 
tumor take (see Figure 5B). Interestingly, high frequency of both IFN-γ- (Figure 9A) and IL-
4-producing (Figure 9B) cells were detected in the spleen of these animals when stimulated 
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in vitro by all stimuli including TS/A parental tumors, the AH1 MHC class I-restricted 
peptide and, particularly, TS/A-CIITA cells. In both cases, responses were strongly inhibited 
by incubation with anti-MHC-II antibodies and to less r extent, with anti-MHC-I antibodies 
(Figure 9A-B, right panels). These results indicate a re-polarization toward a mixed Th1/Th2 
phenotype of the tumor-specific T cells that, at the origin, were mostly polarized toward a Th2 
phenotype (see Figure 8A-B, ACT tum+). 
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4. DISCUSSION 
The aim of this investigation was two fold. First, to assess whether efficacious anti-tumor 
response could be generated against highly tumorigenic cells of different histological origin 
by the CIITA transfection approach, as this is important for envisaging application of this 
vaccination strategy in human settings. Second, to explore the possibility of using immune, 
tumor-specific lymphocytes generated by the CIITA-tumor vaccination approach as 
immunotherapeutic tool for established cancers. 
As far as the first aim, the results presented hereunambiguously show that, in addition to the 
already described TS/A mammary adenocarcinoma (Meazza et al. 2003; Mortara et al. 2006; 
Mortara et al. 2009), tumors as different as colon carcinomas (C51) and sarcomas (WEHI-164) 
could be rendered highly immunogenic and rejectable in vivo by CIITA-mediated gene 
transfer. This marked therapeutic effect, confirmed in three different tumor models, not only 
produces a reduction in tumor size, but results in a significant number of cured animals. 
The results provide unprecedented preclinical experimental data indicating that poorly 
immunogenic tumor cells of different histotype are rejected if they express MHC class II 
antigens induced by stable transfection of the MHC class II transactivator CIITA.  
Interestingly, although CIITA-RENCA tumor cells could not be fully rejected, they grew in
vivo with a significantly reduced kinetics as compared to parental untransfected cells. This 
correlated with the reduction of CIITA-mediated MHC-II expression of the tumor arising in
vivo, as we have shown previously also in the TS/A tumor del (Meazza et al. 2003). Thus, 
the presence of CIITA-induced MHC-II molecules in tumor cells is instrumental to trigger 
antigen-specific antitumor response capable of protecting in vivo the vaccinated animals from 
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tumor take, and, more importantly, to protect them against further rechallenge with parental 
MHC-II negative tumor cells. CIITA-tumor vaccinated mice, indeed, potently reject parental 
untransfected tumors and generate tumor-specific, long –lasting T cells of superior action in 
adaptive immunotherapy. 
CIITA-induced MHC-II-positive tumor cells may act themselves as surrogate antigen 
presenting cells since they have this capability (Mortara et al. 2006), or they may be engulphed 
as necrotic and/or apoptotic bodies by dendritic cells and “fuel”  dendritic cells with 
preformed MHC-II-antigenic peptide complexes with additional and superior stimulating 
capacity for CD4+ tumor-specific T helper cells, as it has been recently suggested (Mortara et 
al. 2009; Dolan et al. 2006). Whatever the mechanism, it appears that CIITA, via its induction 
of tumor cell MHC-II expression, may act as a specific “adjuvant”  (Kim et al. 2008), inducing 
an amplification of the response induced by the TAA, thus bypassing the need of identifying 
the TAA relevant for the tumor rejection. 
The importance of CD4+ T cell priming in generating and maintaining efficient anti-tumor 
response and tumor rejection after CIITA-tumor vaccination, was witnessed by the fact that 
immune CD4+ T cells alone could protect naïve animals from tumor take in adoptive cell 
transfer assays both in the case of WEHI-164 and C51 tumors. This protection was 
accompanied by the elicitation of strong cytolytic a tivity mediated by CD8+ CTL and was 
observed not only in spleen cells of CIITA-tumor vaccinated mice but also in spleen cells of 
naïve mice adoptively transferred with immune CD4+ T cells and challenged with parental 
tumors (Figure 3). Indeed, in these latter mice CTL activity was even stronger than the one in 
similar mice which received immune CD8+ T cells. These results reiterate the importance of 
anti-tumor specific, primed CD4+ T cells in triggering naïve anti-tumor CD8+ T cell 
precursors to become fully differentiated functional CTLs as we have recently observed also 
Valeria Frangione, Ph.D. Thesis 
DISCUSSION Page 52 of 77 
in a different model of therapy-induced tumor vaccination (Balza et al. 2006; Mortara et al. 
2007). Importantly, these results also demonstrate that, once primed, CD4+ T helper cells do 
not need MHC class II expression on tumor cells to be restimulated, strongly suggesting that 
their restimulation and survival in vivo can be maintained by a minimal requirement of tumor 
antigen availability, possibly fulfilled by MHC-II-restricted antigen presentation 
accomplished by classical APCs having engulphed tumor cells as necrotic and/or apoptotic 
bodies, as suggested above. 
The other important aim of this project was to asses  whether tumor-specific lymphocytes 
generated by CIITA-tumor vaccination could be used as immunotherapeutic tool for 
established tumors. 
Although preliminary success in several experimental models served as background to apply 
the adoptive cell therapy (ACT) to human settings (reviewed in Rosenberg et al. 2008), results 
in terms of cure and/or diminution of tumor masses were unsatisfactory, with a possible 
exception of metastatic human melanomas (Dudley et al. 2008). Nevertheless, currently ACT 
approach seems to offer better applicability with respect to strategies such as non-specific 
immune modulation, active immunization with TAA or with a wide variety of immunizing 
vectors although the identification of the best “effector”  for ACT and thus, in turn, the best 
immune stimulation of it still remains an unresolved issue. Within this frame, it seems that the 
polyclonal nature of anti-tumor immune r sponse and the presence of CD4+ T cells are 
fundamental to mediate tumor rejection (Pardoll et al. 1998; Cerundolo , 1999; Pardoll et al. 
2001; Yee et al. 2002; Dudley et al. 2005; Moeller et al. 2005; Perez-Diez et al. 2007). 
In previous studies, we have found that both CD4+ and CD8+ T cells collaboratively 
participated in mediating the regression of the murine CIITA-expressing TS/A mammary 
adenocarcinoma (Mortara et al. 2006). The results presented here indicate that immune 
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effectors, CD4+ T helper cells and CD8+ CTLs, generated by vaccination with CIITA-
transfected tumors are capable to cure and/or significa tly reduce the growth of established 
tumors in the highly aggressive TS/A tumor model.  
Of great importance, the T cells obtained from vaccinated mice were therapeutic also without 
other in vitro activation passages, like treatment with anti-CD3 and IL-2, differently to some 
other approaches of vaccination and ACT (Winter et al. 2003; Tanaka et al. 1999). The first 
finding of note, indeed, is that ACT with whole immune spleen cells undergoing neither 
treatment nor amplification in vitro can still be totally curative in 50% of the animals t day 3 
after tumor inoculum and highly effective in reducing the growth at day 6 after tumor 
inoculum. The negative regulation of the anti-tumor immune response in the less responsive 
animals may depend on the size of the tumor. Spleen c lls from BALB/c mice that were 
treated at day 6, indeed, were shown to be still capable of induce the complete protection 
against TS/A tumor cells in Winn Assay experiments (Figure 5C,D). 
Furthermore, ACT induced proliferation of tumor-specific immune splenocytes in receiving 
mice, leading to rejection of subsequent tumor challenge or to protection from metastasis in 
animals having established tumors. The second finding of note, indeed, is that anti-tumor 
lymphocytes were long-living cells since cells even from day 6 ACT animals, taken one 
month after therapy, were extremely efficient in protecting naïve animals from tumor take in 
adoptive cell transfer assays. Of great importance, this transfer of the tumor-specific 
immunity did not require any other manipulation of the recipient animals, contrary to other 
studies in which hosts received adoptively transferred cells after host lymphodepletion 
treatment. Depletion of immune cells before adoptive cell transfer, indeed, can markedly 
improve the antitumor efficacy of transferred cells, due to several different mechanisms 
(Gattinoni et al. 2006), as the creation of niches for the transferred cells and the elimination of 
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regulatory T cells and endogenous cells that limit homeostatic proliferation of the transferred 
cells, due to competition for activating cytokines, known as the ”cytokine sink” effect 
(Gattinoni et al. 2005; Klebanoff et al. 2005). 
The third finding of note is that CD4+ T cells were remarkably more efficient that CD8+ T 
cells in conferring protection from tumor take. 
The latter finding, along with the fact that a potent anti-tumor CTL response was present in 
these animals (Figure 6), further re-emphasizes the key role of tumor-specific helper signals 
from CIITA-vaccine primed CD4+ T cells in triggering and maintaining the effector function 
of CD8+ CTL naïve precursors, in tumor-bearing ACT treated mice although we cannot 
exclude that primed CD4+ T cells may include as well a subset of cytotoxic CD4+ T cells 
(Cohen et al. 2000). Future studies will further clarify this aspect. 
Assuming that Th1 and Th2 CD4+ T cells have been shown to have distinct roles in various 
immune responses (Nishimura et al. 1999), including antitumor immune responses, further 
phenoytypic and functional characterization of the lymphocyte subpopulations present in mice 
undergoing ACT was performed. It was shown that spleen cells from tumor-cured mice 
displayed a mixed Th1/Th2 phenotype with increased fr quency of both IFN-γ (CD4+ and 
CD8+ T cells) and IL-4 (CD4+ T cells) producing cells, whereas spleen cells from day6 ACT 
mice with retarded tumor growth exhibited a prevalent Th2 phenotype. Interestingly, this 
latter Th2 phenotype switched to a mixed Th1/Th2 phenotype with a strong IFN-γ and IL-4 
type of response when these cells were used for adoptive transfer in virgin animals, in which 
they caused protection from tumor take. The only apparent distinction with the mixed 
Th1/Th2 phenotype observed in ACT tumor-cured mice was the maintenance of the AH1 
peptide-specific component of response in the Th2 type cells. The reasons of this differential 
response are presently matter of investigation. It is important to stress however the fact that 
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switch from a prevalent Th2 to a mixed Th1/Th2 type of response was accompanied by a 
strong increase of cytolytic activity in these spleen cells. 
Taken together, these data strongly suggest that the major anti-tumor immune cells generated 
by our vaccination approach and used for ACT therapy display a modulatable phenotype and, 
depending upon their interaction with the tumor microenvironment and their relative 
proportion with respect to tumor cells, they can re-polarize assuming a more protective 
phenotype when they are Th1 (Mortara et al. 2006) or both Th1/Th2 (Mortara et al. 2009) with 
respect to a less protective phenotype when they are, or they are forced to be, only of the Th2 
phenotype. Several examples of a mixed Th1/Th2 immune response correlating with the 
tumor rejection have been reported (Hung et al. 1998; Schuler et al. 1999; Lopez et al. 2005). 
Interestingly, we recently found that a protective Th1/Th2 type of immune response was also 
observed in mice protected from tumor growth after a therapeutic procedure that targets tumor 
vessels and result in intense necrosis of tumor tissue (Balza et al. 2006; Mortara et al. 2007). 
Thus, it is likely that plasticity of immune effectors, particularly CD4+ T helper cells, is at the 
basis of a protective anti-tumor immune response and provides these cells were originally 
triggered by optimal antigen presentation generated, as in our approach, by CIITA-dependent 
MHC class II expression in tumor cells. 
The immunotherapeutic strategy described here uses autologous tumor cells as the 
immunogen. Not all human malignancies will be amenable to this approach, since not all 
cancers can be cultured or transduced in vitro. However, phase I/II clinical trials using 
autologous tumor cells as immunotherapeutic agents are currently underway for a variety of 
human tumors [neuroblastoma, breast, melanoma, prostate, glioma, papilloma 
(http://cancernet.nci.nih.gov)]. 
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Some results strongly suggest that combination therapi s, such as those involving vaccination 
combined with adoptive T-cell transfer, may produce synergistic antitumor responses that are 
considerably more potent than either approach used in isolation (Overwijk et al. 2003; Parviz et 
al. 2003; Lou et al. 2004; Jorritsma et al. 2008; Tamai et al. 2008; Chen et al. 2009). 
Within this frame, vaccination and therapeutic approaches, both directed to induce specific 
anti-tumor immune responses, are proposed. These approaches are based on CIITA-
genetically engineering tumor cells that become more "immunogenic" and thereby stimulate 
in vivo the generation of tumor-specific effector cells. Results from these strategies suggest 
that the appropriate polarization of effector CD4+ T cells induced by vaccination, could 
enhance the successful tumor eradication by adoptive immunotherapy, after appropriate 
amplification strategies in vitro of tumor-specific vaccine-induced CD4+ T cells (Caserta et al. 
2009). 
In conclusion, tumor cell modification by CIITA may offer an alternative strategy not only for 
preventive vaccination in a wide variety of tumors but also for the generation of superior anti-
tumor immune lymphocytes for adoptive cell therapy. 
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5. FIGURES and TABLES 
 
Figure 1. CIITA-dependent MHC-II expression on tumor cells of different histotype. 
A). Immunofluorescence flow cytometry profiles of CIITA-transfected C51 colon 
adenocarcinoma, RENCA renal carcinoma and WEHI-164 fibrosarcoma tumor cells stained 
for MHC class II molecules (darker histograms) as compared with untransfected controls 
(lighter histograms). B). MHC class II phenotype of ex-vivo tumor cells from C51-CIITA and 
RENCA-CIITA showing that these tumor cells have a reduced expression of MHC class II 
cell surface molecules as result of in vivo down regulation of expression transfected CIITA. 
Cells were stained by indirect immunofluorescence with mAb specific for I-E (K22.422) plus 
FITC-conjugated goat anti-mouse mAb. Dashed histograms represent negative control of an 
irrelevant isotype-matched mAb. 
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Figure 2. CIITA-tumor cell lines are rejected or drastically retarded in their growth in vivo. 
Equal numbers of transfected or parental tumor cells were injected subcutaneously (s.c) in BALB/c 
mice. At least 8 animals were injected per group and o e representative experiment of at least two is 
shown for each tumor model. A) Tumor growth was monitored over time (abscissa) and results 
expressed as percentage of tumor-free mice in the ordinate. B) Tumors arising from CIITA-transfected 
cells, mock-transfected cells or from parental cells were compared for their corresponding size over 
time (abscissa) and results expressed as tumor size (mm2) in the ordinate. Data represent means ± 
SEM of tumor volumes and significant differences from parental tumor group are indicated (*P<0.01). 
Open symbols refer to parental untransfected tumor cells; full symbols refer to CIITA-transfected 
tumor cells. 
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Table 2. Mice rejecting CIITA-tumors are resistant to challenge with parental tumor and 
develop long-lasting immunological memory. 














WEHI-CIITA 10 100 (10/10)* WEHI-164 100 (10/10) WEHI-164 100 (10/10) 
C51-CIITA 10 80 (8/10) C51 100 (8/8)‡ C51 100 (8/8)‡ 
 
* in parenthesis, number of animals injected with CIITA-transfected tumor / number of rejecting mice. 
 
† first and second challenge with corresponding parent l tumors were performed after 30 days and 90 days, 
respectively, from injection of CIITA transfected tumors. 
 
‡ 8 out of 10 mice rejected C51-CIITA tumors. All these mice were resistant to a first and a second challenge 
with parental C51 tumor cells. 
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Figure 3. Role of T lymphocyte subpopulations in anti-tumor immunity after CIITA-vaccine. 
A) Naïve mice were co-injected s.c. with immune total spleen cells, CD4+ or CD8+ T cells and parental 
tumor cells at ratio of 80:1, 40:1, 20:1 (C51) or 1:1, 0,8:1, 0,4:1 (WEHI-164), respectively. Control 
mice (Total control) were co-injected with total splenocytes from naïve animals and tumor cells at 
ratio 80:1 (C51) and 1:1 (WEHI-164). B) Tumor-rejecting mice after injection of listed immune cells 
(see A) were challenged after 30 days with parental C51 or WEHI-164 tumor cells. Total control, 
naïve animals challenged with tumor cells only. Tumor growth was monitored over time (abscissa) 
and the results expressed as percentage of tumor-free mice in the ordinate (A and B, left panels, B 
right panel). Tumors arising in adoptively transferred animals were compared for their corresponding 
size over time (abscissa) and the results expressed a  tumor size (mm2) in the ordinate (A, right 
panels). Data represent means ± SEM of tumor volumes and significant differences from parental 
tumor group are indicated (*P<0.01). At least 8 animals were included per group and one 
representative experiment of at least two is shown for each tumor model. 
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Figure 4. CIITA-vaccine generates potent CTL respones. 
Splenocytes from mice rejecting CIITA-transfected tumors and further resistant to challenge with 
parental tumor (WEHI-CIITA or C51-CIITA), or from mice with growing tumors (WEHI pc or C51 
pc) were taken 20 days from challenge, or at 20 days after tumor inoculum, respectively (A and B). 
Similarly, spleen cells from naïve mice coinjected with tumor cells and total immune splenocytes 
(Total + chall), CD4+ (CD4 + chall) or CD8+ (CD8 + chall) T cells (same animals as Fig.3A), were 
taken 20 days after adoptive transfer (C and D). Spleen cells were co-cultured with mitomycin C-
treated parental tumor cells. Five days after stimulation, splenocytes were recovered and used as 
effector cells. Lactate dehydrogenase (LDH) release assay was used to measure cytotoxicity against 
specific tumor target cells as described in Materials and Methods. Abscissa, effector lymphocytes 
versus tumor cells (E/T) ratio; ordinate, percent of specific lysis 
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Figure 5. ACT of established tumors by CIITA-vaccine induced immune effectors. 
Mice were s.c. injected with 5x104 TS/A tumor cells. At the selected times, freshly isolated total 
splenocytes from mice rejecting CIITA-TS/A and a challenge with parental tumor were used for 
adoptive cell therapy (ACT). Immune cells were injected near the tumor site. Each mouse received 
5x106 total spleen cells. At least 8 animals were included per group. 
A) Tumor growth was monitored over time (abscissa) and the results expressed as percentage of mice 
free of tumor in the ordinate. 
B) Tumors still growing after ACT were compared over time (abscissa) for their corresponding size 
and the results expressed as tumor size (mm2) in the ordinate. Data represent means ± SEM of tumor 
volumes and significant differences from parental tumor group (C day 0) are indicated (*P<0.01). 
After 4-weeks from tumor challenge, a pool of spleen c lls from mice with delayed tumor growth, 
after adoptive therapy on day 6, was used in Winn Assay experiments in which 1x107 total, 3x106 
CD4+ or 2x106 CD8+ cells were mixed to 5x104 TS/A tumor cells. A minimum of 8 animals were 
included per group. 
C) Results were expressed as percentage of tumor-free animals (ordinate) over time. 
D) For those animals which developed a tumor, the results were expressed as tumor size (ordinate) 
over time (abscissa). Data represent means ± SEM of tumor volumes and significant differences from 
total splenocytes of not treated TS/A tumor-bearing mice control group (C sc) are indicated (*P<0.01, 
+P<0.05).  
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Table 3. ACT cured mice develop long-lasting resistance to subsequent tumor challenge. 
ACT group * Tumor free after ACT† Tumor free after challenge‡ 
day 0 8/8 8/8 
day 1 6/8 6/6 
day 3 4/8 4/4 
 
* the listed groups include only those in which complete cure and regression of the tumor was observed. 
 
† ratio between the number of mice undergoing ACT / the number of mice cured from tumor at 30 days after 
ACT. 
 
‡ cured mice were challenged with parental tumor 30 days after first tumor injection. Results are expressed as 
the number of mice undergoing challenge/ the number of mice protected at 60 days after challenge 
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Figure 6. CTL responses in mice undergoing adoptive cell immunotherapy. 
A) Splenocytes from either cured mice or mice displaying reduced growth kinetics after adoptive cell 
immunotherapy (ACT day 3 and ACT day 6, respectively) were assayed at after 30 days from tumor 
inoculum for their CTL activity.  
B) Spleen cells of naïve mice that were coinjected with TS/A tumor cells and immune splenocytes 
from day 6 ACT and that showed no tumor growth (II°Transfer ACT day6), were assayed 30 days 
after coinjection for their CTL activity. Distinct splenocyte populations were incubated with 
mitomycin C-treated TS/A parental tumor cells. Five days after stimulation, splenocytes were used as 
effector cells in the Lactate dehydrogenase (LDH) release assays to measure cytotoxicity against 
specific tumor target cells. CTL activities were compared with the CTL activity of spleen cells from 
untreated, TS/A tumor bearing mice (untreated TS/A tumor). Values are expressed as percent specific 
lysis (ordinate) at the distinct effector/ target ratios listed in the abscissa. 
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Figure 7. ACT induces a massive cellular infiltration of TS/A tumors. 
Cellular infiltrates were analyzed for the presence of  various leukocytes populations, namely CD4+ T 
cells (CD4+), CD8+ T cells (CD8+), dendritic cells (DC), polymorphonucleates (PMN), and 
macrophages (MФ) in TS/A tumor tissues of mice receiving ACT at day 6 and fourteen days after 
tumor inoculum (A). Results are expressed as cell number (mean ± SD) per high magnification 
microscopic field and significant differences from control group are indicated (*P<0.01). White 
columns: untreated mice; black columns: mice treated with adoptive therapy on day 6. Three mice per 
group were used. 
B), Histology of a tumor section showing extensive ar as of necrosis (TS/Apc + ACT, nec) at the time 
of analysis after ACT as compared to tumor tissue of a control mouse injected with TS/Apc and naïve 
spleen cells. Staining with Gill’s hematoxylin. 
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Figure 8. Th1 and Th2 responses in ACT cured or treated mice. 
Tumor-specific IFN-γ- (A, left panel) and IL-4-producing (B, left panel) T cells in the spleens of mice 
cured (ACT tum−) or with delayed tumor growth (ACT tum+) after adoptive cell immunotherapy at 
day 3 or at day 6, respectively. The frequencies of IFN-γ- and IL-4-producing splenocytes were 
evaluated by enzyme-linked immunospot assay (ELISPOT) four weeks post-tumor inoculum. The 
same groups of spleen cells were analyzed for IFN-γ-or IL-4-production in the presence of mAb 
specific for either MHC class I (anti-MHC class I) or class II (anti-MHC class II) molecules (A and B, 
right panels). Before ELISPOT spleen cells were restimulated in vitro for 40 hours with either TS/A 
parental cells (TS/A), TS/A-CIITA transfected cells or with the MHC-I restricted peptide AH1 from 
the gp70 protein of an endogenous retrovirus. Spots were detected using a stereomicroscope and 
values calculated per 106 total spleen cells. Columns, mean spot-forming cells (SFC) of triplicate 
samples; bars, ±SD. 
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Figure 9. Th1 and Th2 responses in naïve mice afterWinn Assay from ACT treated mice. 
Tumor-specific IFN-γ- and IL-4-producing T cells (A and B, left panels) in the spleens of mice 
coinjected with TS/A and splenocytes of day 6 treated ACT animals. These animals were protected 
from tumor take. The assay was conducted after four weeks from coinjection. Spleen cells were also 
analyzed for IFN-γ-or IL-4-production in the presence of mAb specific for either MHC class I (anti-
MHC class I) or class II (anti-MHC class II) molecules (A and B, right panels). Before ELISPOT 
spleen cells were restimulated as described in the leg nd to Figure 9. Spots were detected using a 
stereomicroscope and values calculated per 106 total spleen cells. Columns, mean spot-forming cells 
(SFC) of triplicate samples; bars, ±SD. 
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